MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

The genomic biomarkers market is experiencing rapid growth, driven by advancements in precision medicine, early disease ...

About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers ...

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests ...

SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual ...

SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease ...

NEW YORK — Chicago-based academic health system Northwestern Medicine has struck a deal to collaborate with PathAI on its cloud-based AISight digital pathology image management system, the partners ...

NEW YORK – A tiny obstacle course for immune cells may someday help neonatal intensive care unit clinicians to quickly detect fatal bloodstream infections. Described recently in Pediatric Research, a ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD ...